Medicine and Dentistry
Adverse Event
25%
Alzheimer Disease Assessment Scale
25%
Alzheimer's Disease
100%
Amyloid Protein
16%
Anti-Inflammatory Drug
8%
Apoplexy
8%
Biological Marker
8%
Brain Blood Flow
8%
Calcium Channel Blocking Agent
8%
Clinical Dementia Rating
16%
Clinical Trial
8%
Communication Disorder
8%
Dihydropyridine
8%
Disability
8%
Diseases
8%
Intention-to-Treat Analysis
8%
Mini-Mental State Examination
8%
Mini-Mental State Examination Score
8%
Nervous System Disorder
8%
Nilvadipine
100%
Placebo
41%
Randomized Controlled Trial
100%
Rating Scale
16%
Sustained Drug Release
8%
Tau
8%
Treatment Group
8%
Pharmacology, Toxicology and Pharmaceutical Science
Adverse Event
25%
Alzheimer's Disease
100%
Amyloid Protein
16%
Anti-Inflammatory Drug
8%
Biological Marker
8%
Calcium Channel Blocker
8%
Cerebrovascular Accident
8%
Clinical Trial
8%
Communication Disorder
8%
Dihydropyridine
8%
Disability
8%
Diseases
8%
Nilvadipine
100%
Placebo
41%
Preclinical Study
8%
Randomized Controlled Trial
100%
Sustained Release
8%
Treatment Group
8%
Biochemistry, Genetics and Molecular Biology
Amyloid Protein
16%
Brain Blood Flow
8%
Calcium Channel Blocker
8%
Clinical Trial
8%
Dihydropyridine
8%
Mental Health
16%
Nilvadipine
100%
Preclinical Study
8%
Randomized Controlled Trial
100%
Sustained Drug Release
8%
Tau
8%